VIDEO: Antibody-drug conjugates 'promising' in early-stage breast cancer
In this video, Debu Tripathy, MD, professor and chair of the department of breast medical oncology at The University of Texas MD Anderson Cancer Center and HemOnc Today Editorial Board member, discussed the exciting potential of antibody drug conjugates.
The data was presented at the 38th Annual Miami Breast Cancer Conference.
“This is a promising area that can be used, certainly not only in the advanced setting, but there are also trials now looking at these drugs in the early-stage setting for patients who have residual disease,” Tripathy said. “We can now measure residual disease in the blood using circulating tumor DNA. That technology is being examined as a way to get on top of metastatic disease before it's even detectable by scans, and maybe even eradicating it long-term. Time will tell, but these studies are now underway.”
Collapse
Read more about